David Hutton

If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration and diabetic macular edema.

A team of researchers has now developed an approach to gather and compile a great deal of information about organoids and their development. The team applied its approach to the organoids of the human retina, which they derived from stem cells.

According to researchers, these chronic, progressive retinal diseases, including retinitis pigmentosa, arise from genetic and environmental disruptions of cellular and tissue stability.

According to the organization, the trip marks the 12th training project in Vietnam for the Flying Eye Hospital, including one virtual project on Cybersight, Orbis's telemedicine platform.

At the American Society of Cataract and Refractive Surgery annual meeting in San Diego, data was presented from the STORM study that demonstrate vision quality to be a major driver of the patient decision to undergo surgery.

According to the company, the announcement represents the first FDA-approved, fixed-combination of tropicamide and phenylephrine for mydriasis.

According to the company, a PDUFA date has been set for December 22, 2023.

Scientists at Medical College of Georgia demonstrated in their animal model of retinopathy of prematurity that the small molecule K604, which is being explored in cancer and Alzheimer’s, can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth

Alcon presented details from a new study at the American Society of Cataract and Refractive Surgery’s annual meeting taking place in San Diego, California. The investigator-initiated study led by J. Morgan Micheletti, MD, demonstrated that Clareon and Eyhance monofocal IOLs provide similar range of vision, including distance and intermediate visual acuity.

The study, titled “A Clinical Registry Study of Glaucoma Medication Use in Patients with Mild Glaucoma Severity After MIGS,” will be presented Sunday by Michael Mbagwu, MD, at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, California.

John Berdahl, MD sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his abstract on the Phase 3 trials of iDose TR, versus topical timolol at the ASCRS annual meeting in San Diego.

Ike Ahmed, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation on the study of standalone multiple trabecular micro-bypass stents for uncontrolled glaucoma at the ASCRS annual meeting in San Diego

Penny Asbell, MD, FACS, MBA, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation on the ARMOR study and the antibiotic resistance of intraocular bacterial pathogens at the ASCRS annual meeting in San Diego

According to the companies, the expanded partnership will enhance the MedFlow and MDOffice software suites.

According to the company, outcomes show the potential for its modular, shape changing lens system.

The laser and scanner are completely integrated into a single delivery device that attaches to compatible slit lamps.

David Wallace, MD, MPH, the Marilyn K. Glick Professor and chair of the Department of Ophthalmology for Indiana University School of Medicine, is new chairman of Ophthalmology and Visual Sciences and director of the Vanderbilt Eye Institute for Vanderbilt University Medical Center.

A study of ChatGPT found the artificial intelligence tool answered less than half of the test questions correctly from a study resource commonly used by physicians when preparing for board certification in ophthalmology.

According to the company, BRIMOCHOL PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well-tolerated with no significant adverse events.

ZEPTOLink will be introduced at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego.

According to the company, clinical trials of the ophthalmic gel showed that patients treated with IHEEZO did not require any supplemental treatment to complete the intended surgical procedure. Harrow will host several launch events at the 2023 American Society of Cataract and Refractive Surgery annual meeting being held May 5-8, 2023, in San Diego, California.

Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.

Horizon recently received an updated indication for TEPEZZA to specify its use in patients with TED, regardless of disease activity or duration, coming after the company released positive topline results from the phase four clinical trial of patients with chronic TED.

Ravi Parikh, MD, MPH, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation about adopting dropless cataract surgery to help reduce cost to both patients and the healthcare system at this year's ARVO meeting.

Nazlee Zebardast, MD, MSc sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her research on using machine learning methods to identify image-based, specifically OCT based, phenotypes or structural phenotypes for glaucoma. at this year's ARVO meeting.

Eric Mikula, PhD, from ViaLase sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss the company's femtosecond laser image-guided high-precision trabeculectomy, FLigHT, for non-incisional glaucoma treatment at this year's ARVO meeting.

The Florida Inventors Hall of Fame is celebrating 10 years and will induct 10 inventors, including William W. Hauswirth, PhD, who developed a gene therapy drug to treat children and adults with inherited retinal disease.

David Hutton from Ophthalmology Times and Jay Duker talk about wet AMD and the burdens of treatment on patients thanks to the consistent need for follow-ups and more.

Ram Kannan, PhD, FARVO, principal investigator and adjunct professor of Ophthalmology at David Geffen School of Medicine, UCLA, Doheny Eye Institute, made a pair of presentations at the Association for Research in Vision and Ophthalmology annual meeting in New Orleans. He offers some of the highlights in a conversation with Ophthalmology Times.